Study of adebrelimab, chemo, and apatinib for advanced lung neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and a targeted drug (apatinib) for people with advanced lung neuroendocrine tumors that have not been treated before. The goal is to see if this combination can shrink or slow the growth of the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of lung neuroendocrine tumor that has spread or cannot be removed by surgery.
- You must not have had any previous treatment for your cancer (like chemotherapy or radiation).
- You must be healthy enough to perform daily activities (ECOG score of 0-2).
- You must have at least one tumor that can be measured on a scan.
- You cannot have certain other medical conditions, like uncontrolled heart problems or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of two medications, adebrelimab (an immunotherapy) and apatinib (a targeted therapy), before surgery for people with stage II or III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs (apatinib, adebrelimab, and EC chemotherapy) as the first treatment for extensive-stage small cell lung cancer that has spread. The goal is to see if this combination works better than standard treatments alone.
This trial tests a combination of two immunotherapy drugs (adebrelimab and SHR-8068) plus chemotherapy for people with advanced or spreading non-small cell lung cancer that has certain genetic changes (STK11, KEAP1, or KRAS mutations). It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy, plus Apatinib, a targeted therapy) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.